-+ 0.00%
-+ 0.00%
-+ 0.00%

Inhibrx Biosciences CEO Mark Lappe reports acquisition of 10,040 common shares for $848,976.8365

PUBT·10/14/2026 22:59:06
Listen to the news
Inhibrx Biosciences CEO Mark Lappe reports acquisition of 10,040 common shares for $848,976.8365
  • Inhibrx Biosciences CEO and director Mark Lappe purchased 10,040 common shares through two trusts.
  • Reported purchase prices were $84.0707, $84.9992 and $85.76 per share.
  • His indirect beneficial ownership totaled 970,453 common shares following the purchases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001366074-26-000006), on October 14, 2026, and is solely responsible for the information contained therein.